• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

COVID-19: Dexamethasone trial results confirm both benefits and risks

|

Washington, July 18: The full results from a UK trial of the steroid dexamethasone were published on Friday. It has confirmed its life saving benefits for COVID-19 patients on ventilators, but suggested it may cause harm if given too early.

    Covid vaccine: India begins first stage Covaxin human trials | Oneindia News

    In all 2,104 hospitalised patients were assigned to receive 6 milligram daily doses of the medicine for up to 10 days. 4,321 were to receive usual care, with the rate of deaths compared after 28 days.

    COVID-19: Dexamethasone trial results confirm both benefits and risks

    Among those patients on ventilators, the rate of death for patients on the drug was 29.3 per cent when compared to 41.4 per cent on those without. This means that there was a reduction of 29 per cent in mortality.

    Govt allows use of low-cost steroid 'dexamethasone' for moderate COVID-19 cases

    However, there were no benefits among the group who were not receiving any oxygenation at the time the trial started. 17.4 per cent on the steroid died compared to 14 per cent who did to receive it, suggesting that the drug increased their mortality rate.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X